Home Alzheimer’s Disease Tepotinib in MET exon 14 Skipping NSCLC Induces Durable Responses

Tepotinib in MET exon 14 Skipping NSCLC Induces Durable Responses

Results from subgroup analyses of patients with MET exon 14 skipping non‒small cell lung cancer (NSCLC) from the single-arm, phase 2 study VISION study (NCT02864992) demonstrated durable clinical activity of tepotinib in both treatment-naïve and previously treated disease.1

In these data that were presented during the 2020 World Conference on Lung Cancer (WCLC) Singapore, 152 patients had 9 or more months of follow-up and were assessed for efficacy in Cohort A and 255 were evaluated for safety in Cohorts A and C as of data cut-off of July 1, 2020. Paul K. Paik, MD, clinical director of Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, presented the findings virtually at the meeting.

Patients with advanced, EGFR/ALK wild-type, METex14 skipping NSCLC received oral tepotinib 500 mg once daily. Efficacy outcomes were consistent in patients who received prior…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments